Stockscreener 앱 받기
3.02%
Altimmune Inc 주식(ALT)의 최신 뉴스
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - The Manila Times
When Will Altimmune Report Q4 Earnings? Key Date and Details for Biotech Investors - StockTitan
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH - Seeking Alpha
Investigation announced for Long-Term Investors in shares - openPR
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune (NASDAQ:ALT) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright maintains Buy on Altimmune stock, $12 target - MSN
Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.83 - MarketBeat
BlackRock, Inc.'s Strategic Acquisition of Altimmune Inc Shares - GuruFocus.com
With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns - Yahoo Finance
IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune, Inc. (NASDAQ:ALT) Receives $20.83 Average PT from Analysts - MarketBeat
Exchange Traded Concepts LLC Cuts Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
HC Wainwright Weighs in on Altimmune FY2029 Earnings - MarketBeat
JPMorgan Chase & Co. Decreases Holdings in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune stock rallies 30% on business updates, UBS buy rating - MSN
Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP ... - The Bakersfield Californian
Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire
Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages - EIN News
(ALT) Technical Pivots with Risk Controls - Stock Traders Daily
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
Exclusive: Altimmune Management Reveals Strategic Roadmap at Major Biotech Conference - StockTitan
HC Wainwright Forecasts Altimmune FY2029 Earnings - MarketBeat
Altimmune spikes after presenting data for obesity drug - MSN
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com Australia
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook - MSN
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Altimmune's (ALT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
2 Companies Poised to Capitalize on the Rise of GLP-1 Weight Loss Drugs - Morningstar
Long Term Trading Analysis for (ALT) - Stock Traders Daily
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth? - Simply Wall St
Altimmune's SWOT analysis: pemvidutide stock shows promise in obesity, NASH markets - Investing.com
Altimmune (NASDAQ:ALT) Shares Gap UpTime to Buy? - MarketBeat
Altimmune (NASDAQ:ALT) Now Covered by Stifel Nicolaus - MarketBeat
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel initiates Altimmune stock at Buy on pemvidutide potential - Investing.com
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Geode Capital Management LLC Acquires 74,194 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug - Streetwise Reports
Barclays PLC Raises Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Down 5.9%Here's Why - MarketBeat
Altimmune Could Find A Partner For Its Phase 3 Exercise (NASDAQ:ALT) - Seeking Alpha
(ALT) Technical Data - Stock Traders Daily
Jim Cramer on Altimmune, Inc. (ALT): ‘Healthcare Is So Out Of Fashion’ - Insider Monkey
0.27%
3.05%
자본화:
|
볼륨(24시간):